John F. Ginascol is President & VP at ABBOTT LABORATORIES (ABT). They have made 4 open-market trades across 1 company since 2020, most recently 2023-03-01.
CIK 0001778075
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ABT | 118,380 | $13.7M |
Shares reported on the most recent Form 4, priced at the 2023-03-02 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABT | SELL | 2023-03-01 | 2023-03-02 | $100.70 | $190K | -4.2% | -1.3% | -0.9% |
| ABT | SELL | 2022-12-13 | 2022-12-15 | $112.32 | $1.2M | +0.1% | +5.3% | -9.2% |
| ABT | SELL · 10b5-1 | 2021-03-01 | 2021-03-02 | $120.61 | $42K | -4.1% | -2.3% | -13.1% |
| ABT | SELL · 10b5-1 | 2021-03-01 | 2022-03-02 | $118.16 | $43K | -4.4% | -1.8% | -2.8% |
| ABT | SELL | 2020-04-21 | 2020-04-23 | $96.00 | $12.1M | -1.5% | -5.3% | +6.1% |
| ABT | SELL | 2020-03-02 | 2020-03-03 | $77.66 | $591K | +1.2% | -1.5% | +15.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.